Milan Kalawadia, CEO, North America, at Dr. Reddy’s Laboratories, goes inside the company’s new growth initiatives—and ...

During a live event, Marc S. Hoffmann, MD, discussed outcomes from the SEQUOIA and ELEVATE-TN studies in chronic lymphocytic ...

Last month, Sandoz revealed that the FDA had rejected its biosimilar of Amgen's Neulasta (pegfilgrastim), a longer lasting version of Neupogen. The FDA is set to make a decision over the coming ...

The German drugmaker said the Tyenne approval – its third for a biosimilar after Idacio (adalimumab) and Stimufend (pegfilgrastim) – is a key component of its Vision 2026 strategy aimed at ...

The Company launched itsfirst biosimilar viz. Pegfilgrastim in Russia. It launched 30 new products in the US generics market. It commenced commercialmanufacturing from 2 more areas of Oral Solid ...

Biosimilar Litigations include litigations relating to biosimilar/follow-on products of CDER-listed reference products. Litigations between biosimilar applicants/manufacturers and reference ...

This two-arm prospective phase III open-label trial randomly assigns (1:1) participants with low–tumor burden FL who wish to pursue active management to rituximab versus mosunetuzumab (Fig 1), ...